If you or a loved one developed progressive multifocal leukoencephalopathy (PML) after taking Tysabri in Michigan, you may be wondering what patterns medical researchers have identified. The long-standing tradition of documenting adverse drug events helps us understand real-world risks. This page examines case reports and studies to clarify what the evidence shows about Tysabri PML in Michigan.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal time limits for filing a claim, is essential. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, vision changes, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic link between Tysabri and PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in MS but also impairs normal immune surveillance in the brain. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune cells are unable to enter the brain to control the virus. The presence of anti-JCV antibodies indicates prior exposure to the virus and is a key risk factor for PML development. The boxed warning on Tysabri clearly states the increased risk of PML and identifies the three main risk factors. However, questions about the adequacy of warnings may arise in legal contexts, particularly regarding whether patients and prescribers were fully informed of the magnitude of risk, the need for regular monitoring, and the importance of early detection. The label requires that patients be evaluated three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also mandates that prescribers determine every six months whether patients should continue treatment and submit status reports to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients have developed PML, leading to settlements and litigation.
For patients in Michigan who have developed PML after Tysabri use, the statute of limitations for filing a personal injury lawsuit is generally three years from the date the injury was discovered or should have been discovered. This is governed by Michigan Compiled Laws Section 600.5805. The 'discovery rule' applies, meaning the clock starts when the patient knew or reasonably should have known that the injury was caused by Tysabri. For PML, this could be the date of diagnosis or when symptoms first appeared and were linked to the drug. It is critical for affected patients to consult with an attorney promptly to determine the applicable deadline, as failure to file within the statute of limitations can bar recovery.
Settlements related to Tysabri and PML have been reached in multidistrict litigation and individual cases. Factors that may influence settlement amounts include the severity of the patient's disability, the duration of Tysabri treatment, the presence of risk factors such as anti-JCV antibodies, and the adequacy of monitoring and warnings provided by the prescribing physician. Patients who were not properly screened for anti-JCV antibodies or whose treatment continued beyond two years without appropriate risk-benefit assessment may have stronger claims. The timeline between exposure and documented harm is also relevant; PML typically develops after months to years of Tysabri use, and the label notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Michigan, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally three years from the date the injury was discovered or should have been discovered. This is based on Michigan Compiled Laws Section 600.5805 and the discovery rule. It is important to consult an attorney promptly to ensure your claim is filed within the applicable deadline.
Tysabri carries a boxed warning stating it increases the risk of PML, a severe brain infection caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk factors include anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior immunosuppressant use. The label requires monitoring and immediate discontinuation if PML is suspected.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.